Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071.

Article 
CAS 
PubMed 

Google Scholar 

Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28:463–8.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, et al. Prevalence and clinical characteristics of refractory hypertension. J Am Heart Assoc. 2017;6:e007365.

Article 
PubMed 
PubMed Central 

Google Scholar 

Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98–105.

Article 
PubMed 

Google Scholar 

Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18:1422–8.

Article 
PubMed 

Google Scholar 

Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168:2340–6.

Article 
PubMed 

Google Scholar 

Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med. 2009;169:874–80.

Article 
PubMed 

Google Scholar 

Mesquita-Bastos J, Bertoquini S, Polónia J. Cardiovascular prognostic value of ambulatory blood pressure monitoring in a Portuguese hypertensive population followed up for 8.2 years. Blood Press Monit. 2010;15:240–6.

Article 
PubMed 

Google Scholar 

de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898–902.

Article 
PubMed 

Google Scholar 

De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2013;61:2461–7.

Article 
PubMed 

Google Scholar 

Ayala DE, Hermida RC, Mojón A, Fernández JR. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol Int. 2013;30:340–52.

Article 
CAS 
PubMed 

Google Scholar 

Hermida RC, Ayala DE, Ríos MT, Fernández JR, Mojón A, Smolensky MH. Around-the-clock ambulatory blood pressure monitoring is required to properly diagnose resistant hypertension and assess associated vascular risk. Curr Hypertens Rep. 2014;16:445.

Article 
PubMed 

Google Scholar 

Gijón-Conde T, Graciani A, López-García E, Guallar-Castillón P, Rodríguez-Artalejo F, Banegas JR. Impact of ambulatory blood pressure monitoring on control of untreated, undertreated, and resistant hypertension in older people in Spain. J Am Med Dir Assoc. 2015;16:668–73.

Article 
PubMed 

Google Scholar 

Cardoso CR, Salles GF. Prognostic importance of ambulatory blood pressure monitoring in resistant hypertension: is it all that matters? Curr Hypertens Rep. 2016;18:85.

Article 
PubMed 

Google Scholar 

Hermida RC, Crespo JJ, Otero A, Domínguez-Sardiña M, Moyá A, Ríos MT, Hygia Project Investigators, et al. Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention. Eur Heart J. 2018;39:4159–71.

Article 
PubMed 

Google Scholar 

Cardoso CRL, Salles GC, Salles GF. Prognostic importance of on-treatment clinic and ambulatory blood pressures in resistant hypertension: a cohort study. Hypertension. 2020;75:1184–94.

Article 
CAS 
PubMed 

Google Scholar 

Cardoso CRL, Salles GF. Associations between achieved ambulatory blood pressures and its changes with adverse outcomes in resistant hypertension: was there a J-curve for ambulatory blood pressures? Hypertension. 2021;77:1895–905.

Article 
CAS 
PubMed 

Google Scholar 

Coccina F, Pierdomenico AM, Cuccurullo C, Pizzicannella J, Guagnano MT, Renda G, et al. Prognostic value of non-resistant and resistant masked uncontrolled hypertension detected by ambulatory blood pressure monitoring. J Clin Hypertens. 2022;24:591–7.

Article 
CAS 

Google Scholar 

Mesquita Bastos J, Ferraz L, Pereira FG, Lopes S. Systolic blood pressure and pulse pressure are predictors of future cardiovascular events in patients with true resistant hypertension. Diagnostics. 2023;13:1817.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Kario K, Hoshide S, Narita K, Okawara Y, Kanegae H, Investigators’ network. Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure: the JAMP Study. Hypertension. 2021;78:1781–90.

Article 
CAS 
PubMed 

Google Scholar 

Coccina F, Pierdomenico AM, Cuccurullo C, Pizzicannella J, Trubiani O, Pierdomenico SD. Ambulatory resistant hypertension and risk of heart failure in the elderly. Diagnostics. 2023;13:1631.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646–59.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, ESC Scientific Document Group, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.

Article 
CAS 
PubMed 

Google Scholar 

McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000;83:596–602.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Dunlay SM, Weston SA, Jacobsen SJ, Roger VL. Risk factors for heart failure: a population-based case-control study. Am J Med. 2009;122:1023–8.

Article 
PubMed 
PubMed Central 

Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

Article 
CAS 
PubMed 

Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, CANVAS Program Collaborative Group, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

Article 
CAS 
PubMed 

Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, DECLARE–TIMI 58 Investigators, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.

Article 
CAS 
PubMed 

Google Scholar 

Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, VERTIS CV Investigators, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–35.

Article 
CAS 
PubMed 

Google Scholar 

Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016;68:1355–64.

Article 
CAS 
PubMed 

Google Scholar 

Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-hour blood pressure lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2019;139:2089–97.

Article 
CAS 
PubMed 

Google Scholar 

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.

Article 
CAS 
PubMed 

Google Scholar 

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2012. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315:1533–7.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

Article 
PubMed 
PubMed Central 

Google Scholar 

Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559–73.

Article 
PubMed 

Google Scholar 

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.

Article 
CAS 
PubMed 

Google Scholar 

Egger M, Smith GD, Schneider M, Minder C. Bias in meta­analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.

Article 
CAS 
PubMed 

Google Scholar 

Oliveras A, de la Sierra A. Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens. 2014;28:213–7.

Article 
CAS 
PubMed 

Google Scholar 

Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625–36.

Article 

Google Scholar 

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115.

CAS 
PubMed 

Google Scholar 

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–57.

Article 
CAS 
PubMed 

Google Scholar 

Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.

Article 
PubMed 

Google Scholar 

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, British Hypertension Society’s PATHWAY Studies Group, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25:1021–30.

Article 
PubMed 

Google Scholar 

Chen C, Zhu XY, Li D, Lin Q, Zhou K. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis. Medicine. 2020;99:e21694.

Article 
PubMed 
PubMed Central 

Google Scholar 

Tsujimoto T, Kajio H. Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension. J Am Heart Assoc. 2020;9:e018827.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74.

Article 
PubMed 

Google Scholar 

Ostrominski JW, Vaduganathan M, Selvaraj S, Claggett BL, Miao ZM, Desai AS, et al. Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: The DELIVER Trial. Circulation. 2023. https://doi.org/10.1161/CIRCULATIONAHA.123.065254.